MaxCyte: Milestones a key contributor to 30% top line growth
MaxCyte delivered a consensus-beating 30% uplift in full-year 2019 (FY19) revenues to US$21.6mln underpinned by the release of milestone payments from its commercial partners as programmes advanced through clinical studies, and by a 25% five-year revenue compound annualised growth rate (CAGR). There are a number of positive trends including increasing recognition of the company’s cell engineering technology, which is regarded as the gold standard in non-viral cell engineering, as well as strong momentum from financing in the cell and gene therapy sector, which attracted nearly US$10bn of global financing in 2019. The company’s wholly-owned CARMA Cell Therapies subsidiary is accelerating an independent funding strategy to be completed in 2020, as the lead clinical programme recently advanced into a fourth and final dosing cohort.
Quick facts: MaxCyte Inc
Price: 630 GBX
Market Cap: £486.11 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE